jfm1330 wrote: CEO of Taimed reiterated confidence in sales growth. The only worry is production capacity. Wuxi are producing below expectations because of lower yield than expected in their process. So now Taimed hired Samsung Biologics to be the second manufacturer. They have started a validation experiment and are expected to enter commercial production next year.
So let's pit things clearly. If Trogarzo would have been a huge success of the bat, Taimed wouls not have been able to supply the amount of drug needed. This is an unexpected uncertainty adding up. Easy to understand now why Taimed are quiet with lower than expected sales. We will need clarifications on that from Thera in the next CC in a month.
https://www.chinatimes.com/realtimenews/20190313002880-260410
https://www.samsungbiologics.com/front/eng/main.do
Zhongyu Dongzuo Zhang Nianyuan: AIDS new drugs will lose 800 million in revenue this year
Zhongyu (4147) held a law meeting on the afternoon of the 13th. Dong Fang Zhang Nianyuan said that this year's treatment of AIDS new drug Trogarzo will give Theratechnologies a target of 800 million yuan in revenue; in addition, due to the production yield of Wuxi WuXi PharmaTech Low, the cooperation case that will be commissioned by South Korea's Samsung OEM has entered a validation experiment and is expected to be added to mass production next year.
Zhongyu was temporarily unable to sell anti-AIDS new drug
Trogarzo due to temporary failure of the US drug labeling and packaging foundry Sharp production line. The revenue in the first two months was only 0.62 billion yuan, which affected the stock price.
Zhang Nianyuan said that there are four key factors for Trogarzo's sales growth in the United States, including insurance coverage, publication of important journals, inclusion of indicators to treat Guideline and J-Code for non-oral medications, etc.; according to the marketing partner’s statement two weeks ago, Negotiations with insurance companies have probably been completed. It is expected that the number of drugs will grow this year, and the sales volume will increase significantly in the future, and will rise in the quarter.
Zhang Nianyuan said that the most important issue at present is to solve the production problem. As the yield of Wuxi is not as good as expected, the cost is increased, and the scale of production capacity is too small, and the production and development with Samsung are negotiating, the operation is running smoothly, and it is expected that the amount will be added next year. Production.
(business)